Despite mixed efficacy and tolerance in clinical trials (3, 4), there is continuing interest in HSP90 as a pharmacologic cancer target (5, 6), highlighted by the approval in June 2022 of one HSP90 inhibitor for chemotherapy-relapsed gastro-intestinal stromal tumors in Japan (7, 8). This evidence concerns the gene HSP90AA1 and cancer.